U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H26N2O3.C5H6O5
Molecular Weight 500.5409
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VINCAMINE OXOGLURATE

SMILES

OC(=O)CCC(=O)C(O)=O.[H][C@]12N3CCC[C@@]1(CC)C[C@@](O)(N4C5=CC=CC=C5C(CC3)=C24)C(=O)OC

InChI

InChIKey=ZZIDXUJHLCRNJB-YAFGAGFVSA-N
InChI=1S/C21H26N2O3.C5H6O5/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2;6-3(5(9)10)1-2-4(7)8/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3;1-2H2,(H,7,8)(H,9,10)/t18-,20+,21+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C5H6O5
Molecular Weight 146.0981
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H26N2O3
Molecular Weight 354.4427
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Vincamine is the major alkaloid of Vinca minor. Although vincamine has been used therapeutically for almost three decades, the exact mechanisms of action and its effects are still unknown. Vincamine is a peripheral vasodilator that increases blood flow to the brain. Vincamine is beneficial to the nervous system's cells feeding and protecting processes and is utilized as an adjuvant in case of cerebrovascular insufficiency, age-related psycho-behavioral disorders, post concussion syndrome in head trauma, in case of post-stroke sequels. Vincamine may be used as a dietary nootropic supplement.

Originator

Sources: E. Schlittler, A. Furlenmeier Vincamine, ein alkaloid aus Vinca minor L. Apocynaceae Helv. Chim. Acta, 36 (1953), pp. 2017-2020
Curator's Comment: Vincamine was first isolated from Vinca minor. reference retrieved from https://www.sciencedirect.com/science/article/pii/S0040403900709774

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Oxybral

Approved Use

Oxybral (Vincamine) is indicated to normalize and adapt the cerebral blood flow according to the metabolic needs and in turn improves, regulates and maintains all the brain functions, reflecting better performance physically and intellectually. Vincamine is beneficial to the nervous system's cells feeding and protecting processes and is utilized as an adjuvant in case of cerebrovascular insufficiency, age related psycho-behavioral disorders, post concussion syndrome in head trauma, in case of post-stroke sequels.
PubMed

PubMed

TitleDatePubMed
Screening for new compounds with antiherpes activity.
1984 Oct
[Nimodipine, nifedipine and vincamine improve amnesia induced by anisodine and sodium nitrite in rats and mice].
1986 Oct
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
1997 Jul
Chiral HPLC separation and CD spectra of the enantiomers of the alkaloid tacamonine and related compounds.
2001
[Open-angle glaucoma clinical presentation and management].
2001 Dec
Interventions for normal tension glaucoma.
2003
[Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models].
2003 Nov-Dec
Enhanced tail pinch-induced activation of catecholamine metabolism in the pericerulean area of RU 24722-treated rats.
2004 Dec 24
Catalytic N-sulfonyliminium ion-mediated cyclizations to alpha-vinyl-substituted isoquinolines and beta-carbolines and applications in metathesis.
2005 Jul 8
Stability-indicating methods for determination of vincamine in presence of its degradation product.
2005 Jun 1
Eburnamine derivatives and the brain.
2005 Nov
Measurement and pharmacokinetics of vincamine in rat blood and brain using microdialysis.
2005 Sep 23
Development and application of an automated solution stability assay for drug discovery.
2006 Feb
Syntheses of vinca alkaloids and related compounds. 104. A concise synthesis of (-)-vincapusine.
2006 May 12
Effect of vinpocetine on retrograde axoplasmic transport.
2007
Synthesis of (+/-)-3H-epivincamine via a Rh(II)-triggered cyclization/cycloaddition cascade.
2007 Aug 16
Impaired cognition and attention in adults: pharmacological management strategies.
2007 Feb
Application of unsymmetrical indirect covariance NMR methods to the computation of the (13)C <--> (15)N HSQC-IMPEACH and (13)C <--> (15)N HMBC-IMPEACH correlation spectra.
2007 Oct
Allosteric modulation of muscarinic acetylcholine receptors.
2007 Sep
In vitro anticholinesterase activity of various alkaloids.
2007 Sep-Oct
Mitigation of nociception via transganglionic degenerative atrophy: possible mechanism of vinpocetine-induced blockade of retrograde axoplasmic transport.
2008
Development and validation of an adsorptive stripping voltammetric method for the quantification of vincamine in its formulations and human serum using a Nujol-based carbon paste electrode.
2008 Dec
Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons.
2008 Dec
Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial.
2008 Jun
Simultaneous determination of piracetam and vincamine by spectrophotometric and high-performance liquid chromatographic methods.
2008 Mar-Apr
Smart stability-indicating spectrophotometric methods for determination of binary mixtures without prior separation.
2008 Mar-Apr
Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing.
2009 Apr 17
Seco-tabersonine alkaloids from Tabernaemontana corymbosa.
2009 Feb
Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model.
2009 Summer
Exercise as an intervention for the age-related decline in neural metabolic support.
2010
Aggressive behavior during social interaction in mice is controlled by the modulation of tyrosine hydroxylase expression in the prefrontal cortex.
2010 Dec 15
Separation of vinca alkaloid enantiomers by capillary electrophoresis applying cyclodextrin derivatives and characterization of cyclodextrin complexes by nuclear magnetic resonance spectroscopy.
2010 Dec 15
WITHDRAWN: Interventions for normal tension glaucoma.
2010 Feb 17
Alpneumines A-H, new anti-melanogenic indole alkaloids from Alstonia pneumatophora.
2010 Jun 15
Antinociceptive effect of vinpocetine--a comprehensive survey.
2010 May 30
Brain trace element concentration of rats treated with the plant alkaloid, vincamine.
2010 Sep
Patents

Sample Use Guides

Oxybral (Vincamine) Capsule contains 30 mg of vincamine in a sustained release pellet form. Oxybral (Vincamine) Ampoule for parenteral administration contains 15 mg of vincamine. Dosage in Adult: 1 capsule twice daily, 1 ampoule once or twice daily by IM or slow IV infusion
Route of Administration: Other
In Vitro Use Guide
Metabolic changes in alveolar macrophages and cell injury were evaluated in three studies carried out after 24 hr of gaseous phase culture in normoxia and in anaerobiosis with a possible treatment with 0.01 ug/ml vincamine: 1) ATP content assay by bioluminescence, the witness of cell vitality which decreases significantly in anaerobiosis; 2) Lactate assay which shows the metabolism derivation towards the anaerobic pathways; and 3) Tritiated deoxyglucose (DOG) incorporation, which shows glucose requirements after hypoxic incubation, maintaining or recovering a certain level of energetic activity.
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:17:23 GMT 2023
Edited
by admin
on Sat Dec 16 02:17:23 GMT 2023
Record UNII
EMQ36IS47K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VINCAMINE OXOGLURATE
WHO-DD  
Common Name English
Vincamine oxoglurate [WHO-DD]
Common Name English
EL-485
Code English
OXOVINCA
Brand Name English
VINCAMINE .ALPHA.-KETOGLUTARATE
Common Name English
VINCAMINE 2-OXOGLUTARATE
Common Name English
Code System Code Type Description
FDA UNII
EMQ36IS47K
Created by admin on Sat Dec 16 02:17:23 GMT 2023 , Edited by admin on Sat Dec 16 02:17:23 GMT 2023
PRIMARY
ECHA (EC/EINECS)
259-115-1
Created by admin on Sat Dec 16 02:17:23 GMT 2023 , Edited by admin on Sat Dec 16 02:17:23 GMT 2023
PRIMARY
PUBCHEM
124168
Created by admin on Sat Dec 16 02:17:23 GMT 2023 , Edited by admin on Sat Dec 16 02:17:23 GMT 2023
PRIMARY
SMS_ID
100000156614
Created by admin on Sat Dec 16 02:17:23 GMT 2023 , Edited by admin on Sat Dec 16 02:17:23 GMT 2023
PRIMARY
CAS
54341-01-4
Created by admin on Sat Dec 16 02:17:23 GMT 2023 , Edited by admin on Sat Dec 16 02:17:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID10969437
Created by admin on Sat Dec 16 02:17:23 GMT 2023 , Edited by admin on Sat Dec 16 02:17:23 GMT 2023
PRIMARY
EVMPD
SUB130568
Created by admin on Sat Dec 16 02:17:23 GMT 2023 , Edited by admin on Sat Dec 16 02:17:23 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY